Is BRCA2 p.Glu866= (c.2598A>G) pathogenic?

BRCA2 p.Glu866= (c.2598A>G) is classified Likely benign in BRCA2 (ClinVar, Expert panel, 4 submitters; last evaluated 2017-06-29). Ultra-rare (popmax 0.017%, mid); Associated with breast-ovarian cancer, familial, susceptibility to, 2.

What condition is associated with BRCA2 p.Glu866= (c.2598A>G)?

BRCA2 p.Glu866= (c.2598A>G) is associated with breast-ovarian cancer, familial, susceptibility to, 2, hereditary breast ovarian cancer syndrome, breast cancer (ClinVar).

How common is BRCA2 p.Glu866= (c.2598A>G) in the general population?

BRCA2 p.Glu866= (c.2598A>G) is ultra-rare (popmax 0.017%, mid) (gnomAD).

How is Hereditary breast and/or ovarian cancer syndrome inherited?

Typically Autosomal dominant (Orphanet). A genetic counselor can assess individual risk for a family.

BRCA2 p.Glu866=

c.2598A>G · rs587780549 · VCV233440

Likely benign Expert panel

Classification

Likely benign

ClinVar

Review

Expert panel ★★★☆

ClinVar · 4 submitters

gnomAD v4.1

Rare

ultra-rare (popmax 0.017%, mid)

Conditions

breast-ovarian cancer, familial, susceptibility to, 2

Computational evidence

Protein change
Missense predictors do not apply to this variant type; conservation carries the signal.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 1.4	GERP -4.8, phastCons 0.26
Overall
CADD	3.13	PHRED · no single calibrated threshold — expert panels disagree

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.017% Middle Eastern · 1/5,898 alleles

Overall 6.98e-05% 1/1,433,296 alleles · ultra-rare

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: BRCA2
Protein: p.Glu866=
Coding: c.2598A>G
MANE Select: NM_000059
dbSNP: rs587780549
Type: single nucleotide variant
Location: chr13:32336953 (GRCh38)
Gene constraint: LOEUF 0.803 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Residue 866: the 'interaction with npm1' region

Full BRCA2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

breast-ovarian cancer, familial, susceptibility to, 2 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary breast ovarian cancer syndrome breast cancer hereditary neoplastic syndrome

For Hereditary breast and/or ovarian cancer syndrome (Orphanet):

Inheritance: Autosomal dominant
Onset: Adult, Elderly

Similar variants

BRCA2 p.Glu866Ter Pathogenic ★ same residue
BRCA2 p.Glu866Asp Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Glu866Gln Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Glu866Gly Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Glu866Lys Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Glu866Val Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Glu866fs Pathogenic ★★★ same residue
BRCA2 c.316+1G>T Pathogenic ★★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca2-p-glu866 (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown